Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03226808
Other study ID # CMU2011-09H
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 1, 2013
Est. completion date June 30, 2028

Study information

Verified date December 2023
Source Zimmer Biomet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to obtain clinical performance (outcomes) data and survivorship for commercially available Vivacit-E (HXPE) liners. This will be done by analysis of polyethylene wear, validated outcome measurement tools, radiographs, and reported adverse events data.


Description:

Safety will be evaluated by monitoring the frequency and incidence of adverse events. Performance will be determined by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Vivacit-E HXPE Liner with the Continuum acetabular shell. In addition, the implanted Vivacit-E HXPE Liners will be evaluated for bedding in, and linear and volumetric wear by the Martell 2-D method at 6 weeks and 1, 2, 4, & 5 years postoperatively. Pain and functional performance will be measured using the Harris Hip and High Activity Arthroplasty Scores. Survivorship will be based on removal or intended removal of the device and through analysis of radiographs, and health status will be determined by evaluation of the EQ-5D.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 258
Est. completion date June 30, 2028
Est. primary completion date March 2, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patient is 18 to 60 years of age, inclusive. - Patient is skeletally mature. - Patient qualifies for primary unilateral or bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following: - Osteoarthritis - Avascular necrosis (AVN) - Post-traumatic arthritis - Congenital hip dysplasia - Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s). - Patient is willing and able to provide written informed consent. - Patient is willing and able to cooperate in the required post-operative therapy. - Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent. - Patient has participated in the Informed Consent process and has signed the IRB/EC approved informed consent. Exclusion Criteria: - Patient is unwilling or unable to give consent or to comply with the follow-up program. - Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc. in the affected hip joint(s). - Inflammatory Arthritis - Rheumatoid Arthritis - The patient is: - a prisoner mentally incompetent or unable to understand what participation in the study entails a known alcohol or drug abuser - anticipated to be non-compliant - The patient has an acute, chronic, or systemic infection(s). - The patient has total or partial absence of the muscular or ligamentous apparatus. - The patient has neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation. - The patient has osteoradionecrosis. - The patient has lack of bony structures proximal or distal to the operative joint, so that good implant fixation is unlikely or impossible. - The patient has local bone tumors/cysts in the bone to be retained that the implanting surgeon determines could inhibit implant fixation. - The patient is skeletally immature. - The patient has any concomitant disease that can jeopardize the functioning and the success of the implant. - The patient is known to be pregnant. - The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal (titanium, tivanium, tantalum, cobalt, chromium, nickel) and ceramic.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Vivacit-E Liner
All subjects enrolled will receive the Vivacit-E liner.

Locations

Country Name City State
United States Texas Institute for Hip and Knee Surgery Austin Texas
United States Department of Orthopaedics University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States OrthoCarolina Research Institute Charlotte North Carolina
United States Denver Hip and Knee, Inc. Parker Colorado
United States Rothman Institute Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Zimmer Biomet

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival of the study device; whether or not it is still implanted in the subject Survival is classified as removal of the study device for any reason 10 years
Secondary Incidence of treatment-emergent Adverse Events (safety) Safety is assessed by monitoring the frequency and incidence of all adverse events, with particular focus on those that may be related to the study device. 10 years
Secondary Harris Hip Score Functional outcomes are measured with the Harris Hip Score, including range of motion, pain level, activity levels and patient satisfaction. 10 years
Secondary Patient activity level Patient activity level is assessed with the High Activity Arthroplasty score, filled out by the patient. 10 years
Secondary Patient Quality of Life This is another self-assessment by means of the EQ-5D score, which measures the patient's perceived quality of life. 10 years
Secondary Radiographic analysis Patient x-rays will undergo a Martell analysis by Dr. John Martell to evaluate radiolucencies, osteolysis, sbusidence, cup migration and polyethylene wear. 2 years
See also
  Status Clinical Trial Phase
Completed NCT04657926 - A Trial of APPA in the Treatment of Knee Osteoarthritis Phase 2
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A
Terminated NCT02820766 - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting N/A